Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

ContinuityBiosciences

More Like This

PR Newswire associated0

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies

Diamyd Medical announces expanded financial support from Breakthrough T1D

PR Newswire associated0

Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer

PR Newswire associated0

Metabolon Receives NIH Grant to Develop Advanced Monitoring and Predictive Tools for Type 1 Diabetes Progression

ACCESSWIRE associated3

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

PR Newswire associated0

FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment

PR Newswire associated0

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options